Esc/eas dyslipidaemias declaration of interest

ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - TF Members and Additional Contributors
Relationship
Type of relationship with industry Financial declaration
with Industry
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Platelet inhibition A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Roche : dabigatran A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Pfizer : cardiovascular - Merck Schering Plough : cardiovascular D - Research funding (departmental or institutional).
- Merck : basic research no direct link to products - AstraZeneca : epidemiology no direct link to products A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Pfizer Inc., New York : Autoimmune dyslipidemia - Roche Pharma : Cardiometabolic disease D - Research funding (departmental or institutional).
- Kowa : Dyslipidemia A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca - speaker fees : Crestor A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Boehringer-Ingelheim : Therapeutic Area ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - TF Members and Additional Contributors
Relationship
Type of relationship with industry Financial declaration
with Industry
- Abbott Laboratories : Therapeutic Area A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Pfizer - speakers fees : CVD risk B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- MSD - speaker fee : CVD risk D - Research funding (departmental or institutional).
- MSD : Neither- audit of risk factor control - Pfizer : On-line guideline learning tool A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Pfizer : Cardiovascular Pharmacology - Boehringer-Ingelheim : CV Pharmacology - Merck Sharp & Dohme : CV Pharmacology A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Novartis : Hypertension - Astra Zeneca : Lipids, CV risk, Heart Failure - Pfizer : Lipids, CV risk,Thrombosis, Heart Failure - MSD-SP, Boehringer Ingelheim, Bayer : Lipids, Diabetes A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Novartis : Transplantation - Schering-Plough : Vytorin ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - TF Members and Additional Contributors
Relationship
Type of relationship with industry Financial declaration
with Industry
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Servier : Ivabradin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Takeda : candesartan E - Research funding (personal).
- As a member of the TIMI Study Group I declare that our research group receives funding from a number of companies where I am not the PI. These include: Merck, BMS, Millennium, Nuvelo, Astra Zeneca, CV Therapeutics, Inotek, Schering-Plough, Integrated Ther : rivaroxaban, TIMI 50 A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Bayer Healthcare : anticoagulants - Merck Sharp & Dohme : antilipemics B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Barilla : foods D - Research funding (departmental or institutional).
- Merck Sharp & Dohme : ezetimibe A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- The Medicines Company : Cangrelor ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - TF Members and Additional Contributors
Relationship
Type of relationship with industry Financial declaration
with Industry
- Eli Lilly Lilly/Daiichi Sankyo - speakers fees; advisory board fees (prasugrel) : Prasugrel B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Ticagrelor D - Research funding (departmental or institutional).
- Daiichi Sankyo : Prasugrel A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Roche Pharma, advisory board : CETP inhibitor - MSD - speaker fee : CETP inhibitor, tredaptive - Boehringer Ingelheim - consulting or lecture fees : DDP4 inhibitor - Kowa, consulting or lecture fees : Statins D - Research funding (departmental or institutional).
- MSD : CETP inhibitor A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Pfizer - consulting or lecture fees : Atorvastatin ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - TF Members and Additional Contributors
Relationship
Type of relationship with industry Financial declaration
with Industry
D - Research funding (departmental or institutional).
- Sanofi Aventis : Antidiabetics basal studies - Ethicon Endo Surgery GmbH : Endosurgical equipment - PPD Scand AB/Takeda : Glithazon clinical study - AstraZeneca : Rousuvastatin, and basal cartdiovascular research A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Roche : Rheumatoid arthritis; Aleglitazar - Bayer Schering Pharma : 3rd ESC Asia CVD Symposium - Astra Zeneca : Crestor - Lipid Modification - Merck Sharp & Dohme : Niacin - Lipid Modification - Chugai Pharma UK : Rheumatoid Arthritis - Pfizer : Vernicline - Smoking Cessation D - Research funding (departmental or institutional).
- Pfizer : Varenicline - Smoking Cessation ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - Document Reviewers
Relationship
Type of relationship with industry Financial declaration
with Industry
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Eli Lilly : antithrombotics B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra zeneca : statins A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Crestor - Merck Sharp & Dohme : Inegy, Ezetrol, Zocor B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca : Crestor D - Research funding (departmental or institutional).
- Astra Zeneca : crestor A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Pierre-Fabre : Cardiac Safety of non-cardiovasclar products - Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. - Johnson & Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II - Sigma-Tau (Italy) : Cardiac Safety of an antimalarial drug - MMV (CH) : Cardiac Safety of an antimalarial drug - Santhera (CH) : Cardiac Safety of an antimalarial drug - TROPHOS : DSMB for an investigational drug in Amyotrophic Lateral Sclerosis – Cardiac safety - CEPHALON : DSMB in an oncology phase IIb trial - Jansen-Cilag : Proton-pump inhibitors and drug interactions, including Clopidogrel D - Research funding (departmental or institutional).
Jansen-Cilag : Proton-pump inhibitors and drug interactions with Clopidogrel A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca - speaker fees : Atacand, Ticagrelore ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - Document Reviewers
Relationship
Type of relationship with industry Financial declaration
with Industry
- As a member of the TIMI Study Group I declare that our research group receives funding from a number of companies where I am not the PI. These include: Merck, BMS, Millennium, Nuvelo, Astra Zeneca, CV Therapeutics, Inotek, Schering-Plough, Integrated Ther : Rivaroxaban - Actavis : TrimetazidineB - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- As a member of the TIMI Study Group I declare that our research group receives funding from a number of companies where I am not the PI. These include: Merck, BMS, Millennium, Nuvelo, Astra Zeneca, CV Therapeutics, Inotek, Schering-Plough, Integrated Ther : Rivaroxaban A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Boehringer-Ingelheim : Atrial fibrillation and BP - Takeda Pharmaceuticals : canesartan management of heart failure and CKD - Bristol Myers Squibb : hypertension and kidney disease - Merck Sharp & Dohme : lipid management A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Pfizer : atorvastatin - Astra Zeneca - speaker fees : rosuvastatin and candesartan - Boehringer Ingelheim - speaker fees : telmisartan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Merck Sharp & Dohme : Ezetimibe, Tredaptive B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Merck Sharp & Dohme : IMPROVE-IT study A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Pfizer - speakers fees : atorvastatin ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - Document Reviewers
Relationship
Type of relationship with industry Financial declaration
with Industry
- The Medicines Company - speakers fees : bivalirudin; cangrelor - BRAHMS GmbH - speakers fees : copeptin assay - Boehringer Ingelheim - speakers fees; advisory board fees (dabigatran) : dabigatran - Boston Scientific - speakers fees : none - Eli Lilly Lilly/Daiichi Sankyo - speakers fees; advisory board fees (prasugrel) : prasugrel; abciximab - Bayer - speaker fees; advisory board fees (rivaroxaban) : rivaroxaban - Astra Zeneca - speakers fees; advisory board fees (ticagrelor) : ticagrelor; rosuvastatin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- MSD : Hypolipidemic therary B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Schering-Plough : Hypolipidemic therapy D - Research funding (departmental or institutional).
- Merck Schering Plough : Hypolipidemic therapy A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- GSK : Darapladib B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- GSK : Darapladib A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Servier, Menarini, Abbot, Recordati, Omron, Bayer, GSK, : Hypertension, CHD,AF,CHF B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Swiss Federal Office of Public Health : Consultant for National Nutritional Survey A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Esteve : Lipids ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - Document Reviewers
Relationship
Type of relationship with industry Financial declaration
with Industry
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Novartis - consulting or lecture fees : NAVIGATOR/ASPIRE/ALTITUDE/PARADIGM-HF/VIVIDD studies B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Sanofi Aventis - consulting or lecture fees : Lixisenatide CV study C - Receipt of royalties for intellectual property.
- Bristol Myers Squibb : ARISTOTLE study D - Research funding (departmental or institutional).
- Amgen Inc : RED-HF/TREAT studies E - Research funding (personal).
- F. Hoffman La Roche Ltd : ALECARDIO DSMS - Pfizer - consulting or lecture fees : EMPHASIS study A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- SanofiAventis : Dronedarone A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Les Lab. Servier in Georgia : Spiaker fees - Novartis Pharma Services Group in Georgia : Spieker fees - Berlin-Chemie/MENARINI in Georgia : Spieker fees B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Confidational : Investigator A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Merck Sharp & Dohme - speaker fees : Lipids B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Astra Zeneca - speaker fee : Lipids C - Receipt of royalties for intellectual property.
- Pfizer - speakers fees : Lipids D - Research funding (departmental or institutional).
- Maquette : Balloon pump device ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - Document Reviewers
Relationship
Type of relationship with industry Financial declaration
with Industry
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Genzyme, Shire HGT : cholesterol lowering - Merck Sharp & Dohme : cholesterol lowering A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Kowa : dyslipidemia - Astra Zeneca, Bayer AG, Boehringer-Ingelheim, Daiichi-Sankyo, MSD, Novartis, Pfizer, Sanofi-Aventis, Servier : dyslipidemia, hypertension,antiplatelet,pulmonary hypertension - Actelion - speaker fee : pulmonary hypertension A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Sanofi Aventis : Coagulation ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - Document Reviewers
Relationship
Type of relationship with industry Financial declaration
with Industry
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
ESC Committee for Practice Guidelines 2010-2012
Relationship
Type of relationship with industry Financial declaration
with Industry
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Biologics Delivery Systems, Cordis Corporation a Johnson & Johnson company : Biological Therapy - Biotronik : Implantable Cardiac Electronic Device - EBR Systems : Implantable Cardiac Electronic Device - Impulse Dynamics : Implantable Cardiac Electronic Device - Medtronic : Implantable Cardiac Electronic Device - Sorin : Implantable Cardiac Electronic Device - St. Jude Medical : Implantable Cardiac Electronic Device - Abbott : Implantable Cardiac Electronic Device A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Actelion : Bosentan for PAH treatment in congenital heart disease - AGA : Devices for catheter treatment of congenital heart defects B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Edwards Lifesciences : transcatheter valve implantation A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
ESC Committee for Practice Guidelines 2010-2012
Relationship
Type of relationship with industry Financial declaration
with Industry
D - Research funding (departmental or institutional).
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Daiichi Sankyo : consultant for patient adherence 2009-10 - Eli Lilly : consultant for patient adherence 2009-10 D - Research funding (departmental or institutional).
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Servier : perindopril; support for organisation of scientific meeting A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Pierre-Fabre : Cardiac Safety of non-cardiovasclar products ESC Committee for Practice Guidelines 2010-2012
Relationship
Type of relationship with industry Financial declaration
with Industry
- Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. - Johnson & Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. - Sigma-Tau (Italy) : Cardiac Saftey of an antimalarial drug - Santhera (CH) : Cardiac Saftey of an antimalarial drug - MMV (CH) : Cardiac Saftey of an antimalarial drug - TROPHOS : DSMB for an investigational drug in Amyotrophic Lateral Sclerosis – Cardiac safety - CEPHALON : DSMB in an oncology phase IIb trial - Jansen-Cilag : Proton-pump inhibitors and drug interactions, including Clopidogrel D - Research funding (departmental or institutional).
- Jansen-Cilag : Proton-pump inhibitors and drug interactions with Clopidogrel A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
D - Research funding (departmental or institutional).
- Bayer Healthcare : unresctricted grant for diagnostic kits in suspected cardiovascualar disease - Abbott Laboratories : unresctricted grant for diagnostic kits in suspected cardiovascualar disease - Roche : unresctricted grant for diagnostic kits in suspected heart failure and acute coronary syndrome A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
D - Research funding (departmental or institutional).
- GE Healthcare : Development of imaging agents - Lantheus : Development of imaging agents - Novartis : Development of imaging agents A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
ESC Committee for Practice Guidelines 2010-2012
Relationship
Type of relationship with industry Financial declaration
with Industry
- Merck Sharp & Dohme : Antiarrhythmic agents - Bristol Myers Squibb : Antiplatelet agents - Regado Biosciences : Antithrombotic agents - Abbott - lecture fees : coronary stents B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Merck Sharp & Dohme : Antistaphylococcic vaccine D - Research funding (departmental or institutional).
- Johnson & Johnson : Thoracoscopic devices A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
D - Research funding (departmental or institutional).
D - Research funding (departmental or institutional).
ESC Committee for Practice Guidelines 2010-2012
Relationship
Type of relationship with industry Financial declaration
with Industry
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
D - Research funding (departmental or institutional).
- Bayer : clinical studies atrial fibrillation investigator fee - Johnson & Johnson : inestigator fee, ckinical study, atrial fibrillation - MSD : investgator fee clinical studies hyperlipidemia, SCAD - Glaxo Smith Kline : investigator fee, clinical study , SCAD - Servier : investigator fee, clinical study, coronary artery disease - Jansen-Cilag : investigator fee, clinical study, diabetes CVD - Boehringer Ingelheim : investigator fee, clinicla study, AF ESC Committee for Practice Guidelines 2010-2012
Relationship
Type of relationship with industry Financial declaration
with Industry
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Boehringer-Ingelheim : anticoagulation - Pfizer : anticoagulation, pulmonary hypertension - Bayer Healthcare : pulmonary hypertension, anticoagulation A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Boehringer Ingelheim : Valve prostheses - Edwards Lifesciences : Valve prostheses - Medtronic - Advisory Board : Valve prostheses A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
D - Research funding (departmental or institutional).
ESC Committee for Practice Guidelines 2010-2012
Relationship
Type of relationship with industry Financial declaration
with Industry
This table represents the relevant relationships of the above experts with Industry and other entities that were reported to us at the time of publication of the guidelines.

Source: http://www.cholesterol-statine.fr/pdf/ESC-EAS-Dyslipidaemias-DOI.pdf